La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
80 hedge funds and large institutions have $252M invested in La Jolla Pharmaceutical Company in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 24 increasing their positions, 25 reducing their positions, and 18 closing their positions.
54% more capital invested
Capital invested by funds: $163M → $252M (+$89M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
0% more funds holding
Funds holding: 80 → 80 (0)
3% less call options, than puts
Call options by funds: $1.63M | Put options by funds: $1.69M
4% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$12.9M |
| 2 |
SCM
Sio Capital Management
New York
|
+$9.88M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$7.94M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$4.33M |
| 5 |
VMI
VHCP Management III
New York
|
+$1.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$8.31M |
| 2 |
D.E. Shaw & Co
New York
|
-$3.29M |
| 3 |
SCM
Scopia Capital Management
New York
|
-$3.09M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$2.41M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.03M |
LJPC Hedge Fund Activity: Q2 2019 in Review
80 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q2 2019, worth a combined $252M — up 54% from $163M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new LJPC positions and 18 closed out — a net gain of 2 holders — while 24 added to existing stakes and 25 trimmed.
The largest buyer was RTW Investments, adding an estimated $12.9M. The largest seller was Broadfin Capital, cutting an estimated $8.31M.
- 80 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $252M of La Jolla Pharmaceutical Company stock for Q2 2019, up 54% quarter-over-quarter.
- 20 funds opened new La Jolla Pharmaceutical Company positions in Q2 2019 and 18 closed out, a net change of +2 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q2 2019 was RTW Investments, an estimated $12.9M added.
- The largest La Jolla Pharmaceutical Company seller in Q2 2019 was Broadfin Capital, an estimated $8.31M sold.
Based on aggregated 13F filings for Q2 2019.